British Columbia has over 20 Prostate Cancer Support Groups meet once a month. This group is focused on providing help to Chinese-speaking men, but everyone is welcome. We speak Mandarin, Cantonese and English. We meet on the second Thursday of every month from 7:00pm to 9:00pm at the Richmond Public Library (2/F Brighouse Main Branch, 7700 Minoru Gate, Richmond, BC V6Y 1R8). Please register online at The Richmond Public Library website. Join us for the professional presentation and talk to other men and family members who have been dealing with prostate cancer for weeks, months or even years.

If you want to chat with a survivor one on one, you may drop in our walking club. The Richmond Blue Walkers walk on every Tuesdays and Thursdays 9-11am, 5-10 km along the beautiful river dykes and parks in Richmond (Walk in the Richmond Shopping Centre during the raining days or cold seasons). Click here for the schedule or contact Daniel Leung at 604-836-6423 for the locations and meeting places.

The Prostate Cancer Foundation of BC accepts donation online, please go tohttp://prostatecancerbc.ca/ 捐款請到前列腺癌基金會http://prostatecancerbc.ca/

支援小組乃義工組織我們講普通話廣東話和英語幫助您了解良性前列腺疾病與前列腺癌的病徵預防治療康復與最新醫療硏究等資訊我們每月一次第二個星期四從下午7:009:00在列治文公共圖書館二樓市中心公眾泳池對面舉辦免費聚會邀請中英專業人仕主辦醫療與健康講座交流經驗與分享感受報名請到圖書館網站 或致電604-231-6413 (英語) 604-231-6462(中文)報名

列治文前列腺癌友步行團 每週二和週四早上九時至十一時沿著美麗的河堤和公園散步在下雨天或寒冷季節步行於列治文購物中心)。查詢活動更新請打電話604-836-6423 (Daniel)

This blog is provided as a public service. Any persons using the information or documents provided on the blog do so at their own risk. Reference: Oncology Guide to Reliable Websites

Wednesday, December 16, 2015

可能的前列腺癌治療 Potential prostate cancer treatment developed in B.C. gets big boost

Media Release | December 15, 2015 


A potential treatment for advanced prostate cancer developed by the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) scientists has been licensed to pharmaceutical company Roche, marking UBC’s largest licensing agreement to date.
Artem Cherkasov
Artem Cherkasov
Developed at the Vancouver Prostate Centre, the new drug technology that is in pre-clinical development could one day be used to treat prostate cancers that have become resistant to existing treatments. The Vancouver Prostate Centre is a research hub hosted by UBC and VCHRI and designated a national Centre of Excellence for Commercialization and Research.
“We are thrilled that a potential treatment discovered here in B.C. will be developed further and could help many patients dealing with this disease,” said UBC Interim President Martha Piper. “This agreement is an excellent example of the vital role that universities can play in creating and developing new technologies.”
Paul Rennie
Paul Rennie
When advanced prostate cancer spreads, it becomes metastatic and virtually incurable. Current treatments initially slow the spread of the disease and help prolong a patient’s life but the cancer eventually mutates and becomes resistant to drugs. The new treatment, developed by a research team led by Paul Rennie and Artem Cherkasov, is designed to outsmart the cancer by targeting a site in the cancer cells that is not prone to mutation.
  • Watch Rennie and Cherkasov explain how their new technology works in this video.
“We’re at a stage now that we need the right pharmaceutical partner to help to move this technology from a discovery into a finished product,” said Rennie, a professor in the department of Urologic Sciences at UBC and director of laboratory research at the Vancouver Prostate Centre.
“Licensing a treatment to a company is a critical step in ensuring that new technologies end up helping people who need them,” said Brad Wheeler, technology transfer manager at the University-Industry Liaison Office and lead negotiator on the Roche license.
The licensing agreement also stipulates that research will continue in collaboration with the scientists at the Vancouver Prostate Centre.
“We’ve brought computers into biology and we can see what’s going on before we test it in the lab,” said Cherkasov, associate professor at the department of Urologic Sciences and a senior research scientist at the Vancouver Prostate Centre.
Under the terms of the agreement with Roche, UBC and VCHRI can expect to receive an upfront payment, and up to $141.7 million US in pre-clinical, clinical and sales milestone payments for the first product to reach the market, and royalties thereafter. The scientists will share 50 per cent of the net revenues.
BACKGROUND
The potential new treatment was developed using a new computer technology that can scan a database of millions of different molecules to find the ones that will work best as possible treatments.
The research was funded in part by Prostate Cancer Canada, Prostate Cancer Foundation (U.S.), Safeway Canada, the CIHR’s Proof of Principle commercialization program, and PC-TRiADD.

No comments:

Post a Comment